Investigating lung injury after subarachnoid hemorrhage
Official title: Relationship Between Acute Lung Injury and Pulmonary Hyaluronic Acid Deposition After Subarachnoid Hemorrhage
Run by Tianjin Medical University · NCT06628531 · Data updated 2026-11-12
This study looks at how lung injury happens after a brain bleed to see if a substance called hyaluronic acid plays a role and to find better treatments for patients aged 18 to 80.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 1 site (Tianjin) |
| Status | Recruiting |
| Started | December 1, 2024 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | March 18, 2026 |
| Trial ID | NCT06628531 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 80 diagnosed with subarachnoid hemorrhage within the last 5 days and exhibiting a Hunt-Hess scale of IV or V.
✕Probably not a fit
Patients with a history of traumatic brain injury, lung infections, or other significant health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the mechanisms behind acute lung injury (ALI) that occurs following subarachnoid hemorrhage (SAH). It focuses on understanding the role of hyaluronic acid accumulation in the lungs and its relationship with the pathological progression of lung injury. By examining patients diagnosed with SAH, the study seeks to identify potential therapeutic strategies to improve patient outcomes. The research will involve patients aged 18 to 80 who meet specific inclusion criteria, allowing for a detailed analysis of the condition.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients suffering from lung injuries related to subarachnoid hemorrhage.
How similar studies have gone: While the specific mechanisms of lung injury after SAH are not well-studied, related research on pulmonary injury and hyaluronic acid has shown promise in other contexts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 80 years old with independent behavior ability or authorized legal representative. * A documented diagnosis of SAH within 5 days. * A Hunt-Hess scale of Ⅳ or Ⅴ. * Absence of clinical and etiological evidence of pulmonary infection. Exclusion Criteria: * Pregnant or lactating women. * Present history of traumatic brain injury or intracranial hemorrhage. * Past history of neurological disorders, lung infection within the past six months, cancer, chronic cardiopulmonary diseases, hematological diseases or renal failure. * Have participated in clinical trials in the past 4 weeks. * The investigator considers that not appropriate for inclusion.
Where it's running
-
Tianjin Medical University General Hospital
Tianjin, China Recruiting
Study contacts
- Principal investigator: Yadan Li — Tianjin Huanhu Hospital
- Study coordinator: Xintong Dr. Ge
- Email: xge@tmu.edu.cn
- Phone: 86-13662055012
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based EEG for better stroke and post-cardiac arrest outcomes
Researchers are testing whether a simple subhairline EEG patch plus AI can help predict outcomes after cardiac arrest and detect brain bleeds in stroke patients.
-
Metabolomics biomarkers to predict outcomes after subarachnoid hemorrhage
This study tests whether blood and CSF biomarkers, together with clinical data, can predict recovery a year after spontaneous subarachnoid hemorrhage in adults treated in Lisbon.
-
Identifying causes of organ failure in critically ill patients
This study is trying to find out if a specific type of cell death related to iron is causing organ failure in critically ill patients in the ICU, to help develop new treatments in the future.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.